Maridebart cafraglutide — analytical characterisation
Chromatographic conditions, identity, related substances, presentation, reconstitution and in-use stability.
§6Analytical characterisation
§6.1Chromatographic conditions
- Column
- Size-exclusion chromatography, ion-exchange, and peptide mapping after digestion — the biologic framework, not the peptide framework
- Mobile phase and gradient
- Method-dependent
- Detection
- UV 280 nm; multi-angle light scattering
- Retention
- Not applicable
§6.2Identity by mass spectrometry
Intact mass after deglycosylation; drug-to-antibody ratio determination is a critical quality attribute unique to conjugates[3]
§6.3Related substances and degradation
Table 7. Related substances recorded for Maridebart cafraglutide, with the process or storage route that generates each and its analytical signature.
| Related substance | Origin | Analytical signature |
|---|---|---|
| Drug-to-antibody ratio heterogeneity | Conjugation process | Unique critical quality attribute; determined by mass spectrometry or hydrophobic-interaction chromatography |
| Aggregates | Process or storage | Size-exclusion chromatography |
| Free unconjugated peptide | Incomplete purification | Reverse-phase after separation from the antibody |
| Host-cell protein | Upstream process | Immunoassay |
Degradation routes
- Aggregation
- Deconjugation releasing free peptide
- Fc oxidation and fragmentation
§7Presentation, reconstitution and storage
§7.1Presentation and reconstitution
- Presentation
- Solution for injection (investigational)
- Reconstitution
- Not applicable to research supply
- Storage, lyophilised
- Not applicable
- Storage, reconstituted
- 2–8 °C; freezing destroys an antibody conjugate
- In-use period
- No published data
The Institute includes this monograph partly to draw a boundary: several compounds discussed in supply-side channels as though they were synthetic peptides are in fact biologics whose analysis, stability and reproducibility are governed by an entirely different framework.
§7.2In-use stability
Applicable standards: CEI-MS-01 · CEI-MS-02 · CEI-MS-03 · CEI-MS-04 · CEI-MS-05 · CEI-MS-06. The full series is at methodological standards.
Working calculators: reconstitution and insulin-unit conversion · purity against peptide content · certificate minimum-data checker.
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- United States Pharmacopeial Convention. General Chapter ⟨1225⟩ Validation of Compendial Procedures. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q2(R2) Validation of Analytical Procedures. ICH Harmonised Guideline 2023;Step 4 version, 1 November 2023. identifier not held by the Institute
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q1A(R2) Stability Testing of New Drug Substances and Products. ICH Harmonised Tripartite Guideline 2003;Step 4 version. identifier not held by the Institute
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research 2010;27(4):544–575. doi:10.1007/s11095-009-0045-6 · PMID 20143256
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.